米诺地尔治疗化疗所致脱发的随机试验。
A randomized trial of minoxidil in chemotherapy-induced alopecia.
作者信息
Duvic M, Lemak N A, Valero V, Hymes S R, Farmer K L, Hortobagyi G N, Trancik R J, Bandstra B A, Compton L D
机构信息
Department of Medical Specialties, University of Texas, M. D. Anderson Cancer Center, Houston 77030, USA.
出版信息
J Am Acad Dermatol. 1996 Jul;35(1):74-8. doi: 10.1016/S0190-9622(96)90500-9.
BACKGROUND
Hair loss is a side effect of many chemotherapeutic agents, and patients have even refused possibly palliative or lifesaving drugs because they could not accept temporary or prolonged baldness. Topical minoxidil has been shown to be effective for androgenetic alopecia and alopecia areata.
OBJECTIVE
Our purpose was to investigate the value and safety of minoxidil in chemotherapy-induced hair loss.
METHODS
Twenty-two women who were facing adjuvant chemotherapy after breast surgery were registered in a protocol that used a 2% minoxidil topical solution or a placebo in a randomized double-blind trial.
RESULTS
There was a statistically significant difference (favoring minoxidil) in the interval from maximal hair loss to first regrowth. Thus the period of baldness was shortened (mean, 50.2 days) in the minoxidil group.
CONCLUSION
Minoxidil decreased the duration of alopecia caused by chemotherapy. There were no significant side effects.
背景
脱发是许多化疗药物的副作用，患者甚至因无法接受暂时或长期脱发而拒绝使用可能具有姑息或救命作用的药物。外用米诺地尔已被证明对雄激素性脱发和斑秃有效。
目的
我们的目的是研究米诺地尔在化疗所致脱发中的价值和安全性。
方法
22名乳腺癌手术后面临辅助化疗的女性被纳入一项方案，该方案在随机双盲试验中使用2%米诺地尔外用溶液或安慰剂。
结果
从最大脱发量到首次再生长的间隔时间存在统计学显著差异（米诺地尔组更具优势）。因此，米诺地尔组的脱发期缩短（平均50.2天）。
结论
米诺地尔缩短了化疗所致脱发的持续时间。没有明显的副作用。
Zotero 插件